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Abstract
Background: Biofilms are surface-attached groups of microbial cells that are embedded in an extracellular matrix. One of the main features of biofilms is 
their resistance to antimicrobial drugs; therefore, the biofilm-based infections are extremely difficult to treat. This study aimed to investigate the biofilm-
forming capacity of Staphylococcus spp. and Candida spp. strains isolated from collected clinical samples, as well as to assess their antibiotic susceptibility.
Material and methods: The study was conducted on 134 strains of Staphylococcus spp. and 147 strains of Candida spp. isolated from various clinical 
specimens. Both biofilm formation and antibiotic susceptibility of the isolated strains were studied using contemporary standardized microbiological 
methods.
Results: The results of the study showed a high biofilm-forming capacity among the clinical strains of Staphylococcus spp. and Candida spp., as well as a 
higher level of antibiotic resistance in biofilm-producing strains compared to biofilm non-producing ones. 
Conclusions: The high rates of antibiotic resistance and biofilm-forming capacity of strains represent a major public health challenge. The study showed 
a strong correlation between biofilm formation and antimicrobial resistance patterns. 
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Introduction
The advancement of biomedical science has enabled to 
study the microorganisms in their natural environment, 
whereas over 95% of microorganisms existing in nature are 
in biofilms [1]. Biofilm formation is an important strategy 
by which microorganisms survive and adapt in natural en-
vironments [2, 3].
A biofilm is defined as an aggregate of microorgan-
isms in which the cells adhere to each other on a surface, 
enclosed in a synthetized extracellular polymeric substance 
matrix. Biofilms can occur on living or non-living surfaces, 
being widely spread in nature. The vast majority of bacterial 
infections may also involve microbial biofilm formation [4].
Bacteria living in a biofilm usually have significantly 
different properties from free-floating bacteria of the same 
species, being protected by a dense biofilm structure, which 
allows them to cooperate and interact in different manners. 
The main features of the biofilms are their high resistance 
to disinfectants and antimicrobial drugs; whereas the thick 
extracellular matrix and the outer layer cells protect the in-
terior of the community [5].
Most microorganisms form biofilms as a means of re-
sponse to a number of factors, including cellular recognition 
of specific or non-specific attachment sites on a surface nu-
tritional index, or in some cases, by exposure of planktonic 
cells to sub-inhibitory concentrations of antibiotics [6, 7].
It is estimated that microbial biofilms play a major role 
in over 80% of infections. Sixty percent of healthcare-asso-
ciated infections are due to biofilm formation on medical 
implants. Moreover, many chronic diseases are associated 
with biofilms, such as infectious endocarditis, cystic fibrosis 
pneumonia, periodontitis, chronic rhinosinusitis, trophic 
ulcers and otitis media [8].
Staphylococci, predominantly Staphylococcus aureus and 
Staphylococcus epidermidis, are the disease-causing agents in 
a series of infections, which are often associated with chro-
nicity, difficulty to eradicate and antimicrobial resistance 
[9]. Staphylococci are ranked first among the etiological fac-
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tors of bacterial infections, along with the annual increase 
in the number of methicillin-resistant staphylococci (MRS) 
strains and the occurrence of new antibiotic-resistant bacte-
rial strains, which place this pathology among the emerging 
infectious diseases [10].
Staphylococcus aureus is an opportunistic pathogen, 
commonly involved in skin and soft tissue infections. It 
could be detected in the nasopharynx, skin, eyes, intestine 
and urogenital tract as part of the normal flora; although 
in some cases, it might pass through the skin barriers of 
wounds or surgical incisions, causing infections. In addi-
tion, it has the property to adhere and form biofilms on tis-
sues or medical devices. Coagulase-negative staphylococci 
(CoNS) are considered saprophytic, avirulent or low-viru-
lent microorganisms. However, over the past three decades 
there has been an increase in human infections caused by 
CoNS, particularly of S.epidermidis [11].
Levuriform fungi of the genus Candida are found as part 
of the normal flora in healthy individuals and are involved 
in the etiology of opportunistic infections, resulting in high 
mortality rates, particularly in immunocompromised indi-
viduals [12]. Candida species are most commonly associated 
with human diseases due to both virulence factors and bio-
film-forming ability. Candida spp. causes systemic diseases 
and is the fourth most common cause of hospital-acquired 
blood infections. Candida albicans is the most commonly 
found species in fungal infections, whereas other species 
are involved to a lesser extent. However, the increased rate 
of non-Candida albicans isolation and antimicrobial resis-
tance has become a major challenge for clinicians over the 
recent years [13].
Most infections caused by Candida spp. are related to 
biofilm formation on the mucosal surfaces and contami-
nated medical devices. Some study results revealed that the 
biofilms, formed by Candida spp. may become resistant to 
antifungal drugs, including amphotericin B, fluconazole, 
flucytosine, itraconazole and ketoconazole [14].
Therefore, a current in vitro study of the biofilm-forming 
ability associated with the antimicrobial resistance patterns 
of Candida spp. and Staphylococcus spp. strains isolated 
from various clinical biosubstrates is required for the effi-
cient management of these infections.
Material and methods
There have been examined 134 strains of Staphylococ-
cus spp. (88 – S. aureus, 46 – S. epidermidis) and 147 strains 
of Candida spp. (75 – C. albicans, 24 – C. glabrata, 22 – 
C. krusei, 14 – C. parapsilosis, 12 – C. tropicalis), isolated 
from clinical biosubstrates (blood, trophic ulcers, infected 
wounds, and vaginal secretions) and which have been iden-
tified by standard microbiological techniques [15].  
Antimicrobial susceptibility testing and the result 
interpretation were carried out according to EUCAST (The 
European Committee on Antimicrobial Susceptibility Tes-
ting) by using both qualitative methods (Kirby-Bauer disk 
diffusion assay) and quantitative methods determining 
the minimum inhibitory concentration (E-test, Vitek 2 
Compact) [16].
Staphylococcus spp. strains were tested for benzylpeni-
cillin, gentamicin, norfloxacin, cefoxitin, chloramphenicol, 
erythromycin, clindamycin, tetracycline, rifampicin, line-
zolid and vancomycin, whereas Candida spp. strains were 
assessed to fluconazole, itraconazole, amphotericin B, mica-
fungin and flucytosine.
Bacteria that showed resistance to at least one prepara-
tion out of three or more antimicrobial groups were iden-
tified as multidrug resistant strains (MDR) in accordance 
with the guidelines recommended by the joint initiative of 
the European Center for Disease Prevention and Control 
(ECDC) and the Centers for Disease Control and Preven-
tion (CDC) [17]. The methicillin-resistant or methicillin-
sensitive (MSS) patterns of Staphylococcus spp. strains were 
determined according to the inhibition zone diameters of 
cefoxitin disk (30mg), based on EUCAST: MSS if the diam-
eter is at least 22 mm; MRS if less than 22 mm. A double 
disc diffusion test (D test) was used for detecting inducible 
resistance to clindamycin. The erythromycin (15mg) and 
clindamycin (2mg) discs are placed at a distance of 12-20 
mm measured from the edges of the discs. A flattening of 
the zone of inhibition around the clindamycin disk (D test 
positive) is reported as a clindamycin-resistance [18].
Biofilm production by isolated strains was quantitative-
ly determined using the microtiter plate method [19]. For 
the purpose of study, 150µl of peptonate broth and 15µl of 
bacterial suspension were added to a 96 well plate and ad-
justed to the 0.5 McFarland turbidity standard (respectively 
1.5x108 CFU/ml), which were previously prepared from 
18-24 hour bacterial culture and  grown on 5% blood agar. 
The plates were coated and incubated for 24 hours at 37° 
C. Subsequently, the level of adhesion of the tested strains 
to inert substrate was determined by removing the content 
from each well and then rinsing five times with sterile sa-
line and fixing with cold methanol for 5 minutes. After re-
moving of the methanol, the dried plates were stained with 
0.1% violet crystal solution for 30 minutes. The excess stain 
was removed by washing and the stained biofilm was re-
suspended in a 33% glacial acetic acid solution. Thus the 
obtained suspensions were used to determine the optical 
density (OD), based on the spectrophotometric absorbance 
readings at 570 nm colored suspension (A570). The tests 
were performed in duplicate.
The optical density cut-off value (ODc) is defined as the 
average OD of negative control + 3x the standard deviation 
(SD) of negative control. Biofilm formation by the tested 
strains was assayed and classified according to the adsorp-
tion of the violet crystal dye. The isolates were classified into 
four categories: non-adherent (OD ≤ ODc), poor adherent 
(ODc <OD ≤ 2xODc), moderately adherent (2xODc <OD 
≤4xODc) and strongly adherent (4xODc <OD).
The reference strains Staphylococcus aureus (ATCC 
25923), Candida albicans (ATCC 10231) and Candida tropi-
calis (ATCC 750) were used for quality control. EpiInfo 
2000 was used in statistical data analysis.
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Results
The antimicrobial susceptibility testing results of 134 
strains of Staphylococcus spp., revealed that 92 (68.6%) were 
polyresistant to antibiotics, 69 (51.5%) were methicillin-re-
sistant, and 32 (23.9%) were D-test positive.
Staphylococcus spp. strains showed the highest sensitiv-
ity levels to vancomycin (100%), followed by tetracycline 
(88.8%), linezolid (83.6%) and chloramphenicol (82.8%) 
(fig. 1).
Invasive candidiasis is usually treated with five main 
groups of antifungal drugs, including azoles, polyenes, al-
lylamines, echinocandins and pyrimidine analogues [20]. A 
study, conducting a susceptibility testing for Candida spe-
cies to fluconazole, voriconazole, itraconazole, ketoconazole 
and flucytosine, showed that most Candida spp. strains were 
sensitive to fluconazole and flucytosine [21].
The studied Candida spp. strains showed different levels 
of susceptibility to the tested antimycotics. The data anal-
ysis showed the highest level of resistance to itraconazole 
(87.7%) and fluconazole (87.1%), followed by amphotericin 
B (10.9%) and micafungin (2.7%). All tested strains were 
found to be sensitive to flucytosine (fig. 2).
C. tropicalis (41.7%). 44 (50.6%) of Candida spp. strains pro-
duced strong biofilms, 29 (33.3%) – moderate biofilms and 
14 (16.1%) – weak biofilms (fig. 4).
Fig. 1.  Antibiotic resistance of Staphylococcus spp. (%).
Fig. 2.  Antibiotic resistance of Candida spp. (%).
The next stage of the study determined the biofilm for-
mation ability of Staphylococcus spp. and Candida spp. Of 
the 134 tested staphylococcus strains, 77 (57.5%) produced 
detectable biofilms. The biofilm status referred to 27 (35.1%) 
of isolates, which produced strong biofilms, 32 (41.6%) – 
moderate biofilms and 18 (23.4%) – weak biofilms (fig. 3).
Candida spp. strains produced detectable biofilms in 
59.2%. The highest level of biofilm formation ability was re-
corded in C.glabrata strains (95.8%), followed by C. parap-
silosis (57.1%), C. krusei (54.5%), C. albicans (52.0%) and 
Fig. 3.  The biofilm formation capacity of Staphylococcus spp. (%).
Fig. 4.  Biofilm formation capacity of Candida spp. (%).
It is a well-known fact that bacterial populations in bio-
films are considerably more resistant to antibiotics than 
planktonic cells [22]. Thus, biofilm-producing Staphylococ-
cus spp. strains showed a higher antibiotic resistance com-
pared to non-producing strains: benzylpenicillin (100% vs. 
94.7%), gentamicin (61.0% vs. 0%), erythromycin (94.8 % 
vs 45.6%), tetracycline (19.5% vs 0%), cefoxitin (68.8% vs 
42.1%), clindamycin (38.9 vs 3.5%), norfloxacin (90.9% vs 
47.4%), chloramphenicol (27.3% vs 0%), rifampicin (81.7% 
vs 29.8%) and linezolid (25.9% vs 3.5%). All strains were 
found sensitive to vancomycin (tab. 1).
Comparison of biofilm formation ability between methi- 
cillin-resistant (MRS) and methicillin-sensitive (MSS) iso-
lates of Staphylococcus spp. was carried out.  The quantita-
tive and qualitative results showed higher biofilm formation 
ability in MRS strains for both S.aureus and S. epidermi-
dis strains compared to MSS bacteria. Biofilm-producing 
strains revealed a higher antibiotic resistance, which may 
lead to treatment failures in MRS infections (tab. 2).
The studies on Candida spp. strain resistance to antifun-
gal drugs, as well as biofilm formation capacity, showed a 
statistical correlation between biofilm formation capacity 
and antifungal susceptibility (p <0.05) (tab. 3).
Flucytosine is known to inhibit both ribonucleic acid 
and deoxyribonucleic acid synthesis [23] and was the most 
effective antifungal agent against biofilm-producing Can-
dida strains, tested within the present study.
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Table 2
Biofilm formation capacity of MRS and MSS Staphylococcus spp.
Biofilm production
S.aureus S.epidermidis
MRSA
n (%)
MSSA
n (%)
Total
n (%)
MRSE
n (%)
MSSE
n (%)
Total
n (%)
Strong 16 (26.2) 7 (11.5) 23 (37.7) 4 (25.0) 0 (0) 4 (25.0)
Moderate 17 (27.9) 8 (13.1) 25 (41.0) 6 (37.5) 1 (6.3) 7 (43.7)
Weak 7 (11.5) 6 (9.8) 13 (21.3) 3 (18.7) 2 (12.5) 5 (31.3)
Note: MRSA – methicillin resistant S. aureus; MSSA – methicillin sensitive S. aureus; MRSE – methicillin resistant S. epidermidis; MSSE – methicillin 
sensitive S. epidermidis.
 Table 3
Antimicrobial resistance of biofilm- producing and non-producing Candida spp. strains
Antimicrobials
n (%)
Biofilm-producing strains (N=87) Biofilm-nonproducing strains (N=60) p-value
n (%)
Azoles
Fluconazole
Intraconazole
87 (100)
87 (100)
41 (68.3)
42 (70.0)
p<0.0001*
p<0.0001*
Polyenes
Amphotericin B 15 (17.2) 1 (1.7) NA
Echinocandins
Micafungin 4 (4.6) 0 (0) p>0.05
Pyrimidine analogue
Flucytosine 0 (0) 0 (0) NA
Note: *Statistically significant (p<0.05); NA – not applicable. 
Table 1
Antibiotic resistance of biofilm-producing and non-producing Staphylococcus spp.
Antimicrobials
Biofilm-producing strains (N=77)
Biofilm-nonproducing strains 
(N=57) p-value
n (%) n (%)
Penicillins
Benzylpenicillin 77 (100) 54 (94.7) p>0.05
Aminoglycosides
Gentamicin 47 (61.0) 0 (0) p<0.0001*
Macrolides
Erythromycin 73 (94.8) 26 (45.6) p<0.0001*
Tetracyclines
Tetracycline 15 (19.5) 0 (0) p>0.05
Cephalosporins
Cefoxitin 53 (68.8) 24 (42.1) p<0.05*
Lincosamides
Clindamycin  30 (38.9) 2 (3.5) p>0.05
Fluoroquinolones
Norfloxacin 70 (90.9) 27 (47.4) p<0.0001*
Miscellaneous agents
Chloramphenicol
Rifampicin
21 (27.3)
76 (81.7)
0 (0)
17 (29.8)
p<0.05* 
p<0.0001*
Oxazolidinones
Linezolid 20 (25.9) 2 (3.5) p>0.05
Glycopeptides
Vancomycin 0 (0) 0 (0) NA
Note: *Statistically significant (p<0.05); NA – not applicable. 
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Conclusions
The study results revealed a higher biofilm formation ca-
pacity in the clinical strains of Staphylococcus spp. and Can-
dida spp. as well as higher rates of antimicrobial resistance 
in biofilm-producing strains compared to non-producing 
ones. The obtained data proves a strong correlation between 
biofilm formation capacity and antimicrobial resistance pat-
terns. The implementation of the relevant antimicrobial sus-
ceptibility testing of biofilm-producing strains will improve 
the management of infections caused by these microorgan-
isms, as well as provide feasible strategies to prevent their 
spread.
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